Literature DB >> 25480554

Chemokines in cancer.

Melvyn T Chow1, Andrew D Luster2.   

Abstract

Chemokines are chemotactic cytokines that control the migration of cells between tissues and the positioning and interactions of cells within tissue. The chemokine superfamily consists of approximately 50 endogenous chemokine ligands and 20 G protein-coupled seven-transmembrane spanning signaling receptors. Chemokines mediate the host response to cancer by directing the trafficking of leukocytes into the tumor microenvironment. This migratory response is complex and consists of diverse leukocyte subsets with both antitumor and protumor activities. Although chemokines were initially appreciated as important mediators of immune cell migration, we now know that they also play important roles in the biology of nonimmune cells important for tumor growth and progression. Chemokines can directly modulate the growth of tumors by inducing the proliferation of cancer cells and preventing their apoptosis. They also direct tumor cell movement required for metastasis. Chemokines can also indirectly modulate tumor growth through their effects on tumor stromal cells and by inducing the release of growth and angiogenic factors from cells in the tumor microenvironment. In this Masters of Immunology primer, we focus on recent advances in understanding the complex nature of the chemokine system in tumor biology with a focus on how the chemokine system could be used to augment cancer immunotherapeutic strategies to elicit a more robust and long-lasting host antitumor immune response. ©2014 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25480554      PMCID: PMC4258879          DOI: 10.1158/2326-6066.CIR-14-0160

Source DB:  PubMed          Journal:  Cancer Immunol Res        ISSN: 2326-6066            Impact factor:   11.151


  76 in total

1.  Selective depletion of Foxp3+ regulatory T cells improves effective therapeutic vaccination against established melanoma.

Authors:  Katjana Klages; Christian T Mayer; Katharina Lahl; Christoph Loddenkemper; Michele W L Teng; Shin Foong Ngiow; Mark J Smyth; Alf Hamann; Jochen Huehn; Tim Sparwasser
Journal:  Cancer Res       Date:  2010-10-05       Impact factor: 12.701

Review 2.  Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm.

Authors:  Subhra K Biswas; Alberto Mantovani
Journal:  Nat Immunol       Date:  2010-09-20       Impact factor: 25.606

3.  Tumour hypoxia promotes tolerance and angiogenesis via CCL28 and T(reg) cells.

Authors:  Andrea Facciabene; Xiaohui Peng; Ian S Hagemann; Klara Balint; Andrea Barchetti; Li-Ping Wang; Phyllis A Gimotty; C Blake Gilks; Priti Lal; Lin Zhang; George Coukos
Journal:  Nature       Date:  2011-07-13       Impact factor: 49.962

4.  Breast cancer lung metastasis requires expression of chemokine receptor CCR4 and regulatory T cells.

Authors:  Purevdorj B Olkhanud; Dolgor Baatar; Monica Bodogai; Fran Hakim; Ronald Gress; Robin L Anderson; Jie Deng; Mai Xu; Susanne Briest; Arya Biragyn
Journal:  Cancer Res       Date:  2009-06-30       Impact factor: 12.701

5.  Chemotherapy induces intratumoral expression of chemokines in cutaneous melanoma, favoring T-cell infiltration and tumor control.

Authors:  Michelle Hong; Anne-Laure Puaux; Caleb Huang; Laure Loumagne; Charlene Tow; Charles Mackay; Masashi Kato; Armelle Prévost-Blondel; Marie-Françoise Avril; Alessandra Nardin; Jean-Pierre Abastado
Journal:  Cancer Res       Date:  2011-09-26       Impact factor: 12.701

6.  The CXCR3 targeting chemokine CXCL11 has potent antitumor activity in vivo involving attraction of CD8+ T lymphocytes but not inhibition of angiogenesis.

Authors:  Paul J Hensbergen; Pepijn G J T B Wijnands; Marco W J Schreurs; Rik J Scheper; Rein Willemze; Cornelis P Tensen
Journal:  J Immunother       Date:  2005 Jul-Aug       Impact factor: 4.456

7.  PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors.

Authors:  Michael A Curran; Welby Montalvo; Hideo Yagita; James P Allison
Journal:  Proc Natl Acad Sci U S A       Date:  2010-02-16       Impact factor: 11.205

8.  CXCR4 regulates growth of both primary and metastatic breast cancer.

Authors:  Matthew C P Smith; Kathryn E Luker; Joel R Garbow; Julie L Prior; Erin Jackson; David Piwnica-Worms; Gary D Luker
Journal:  Cancer Res       Date:  2004-12-01       Impact factor: 12.701

9.  Macrophages may promote cancer growth via a GM-CSF/HB-EGF paracrine loop that is enhanced by CXCL12.

Authors:  Antonella Rigo; Michele Gottardi; Alberto Zamò; Pierluigi Mauri; Massimiliano Bonifacio; Mauro Krampera; Ernesto Damiani; Giovanni Pizzolo; Fabrizio Vinante
Journal:  Mol Cancer       Date:  2010-10-14       Impact factor: 27.401

10.  PD-1, but not PD-L1, expressed by islet-reactive CD4+ T cells suppresses infiltration of the pancreas during type 1 diabetes.

Authors:  Kristen E Pauken; Marc K Jenkins; Miyuki Azuma; Brian T Fife
Journal:  Diabetes       Date:  2013-04-04       Impact factor: 9.461

View more
  168 in total

Review 1.  Immunotherapy and tumor microenvironment.

Authors:  Haidong Tang; Jian Qiao; Yang-Xin Fu
Journal:  Cancer Lett       Date:  2015-10-19       Impact factor: 8.679

2.  Prostate cancer cells hyper-activate CXCR6 signaling by cleaving CXCL16 to overcome effect of docetaxel.

Authors:  Neeraj Kapur; Hina Mir; Guru P Sonpavde; Sanjay Jain; Sejong Bae; James W Lillard; Shailesh Singh
Journal:  Cancer Lett       Date:  2019-04-08       Impact factor: 8.679

Review 3.  Inflammation and prostate cancer: friends or foe?

Authors:  Gianluigi Taverna; Elisa Pedretti; Giuseppe Di Caro; Elena Monica Borroni; Federica Marchesi; Fabio Grizzi
Journal:  Inflamm Res       Date:  2015-03-19       Impact factor: 4.575

4.  Structure-function guided modeling of chemokine-GPCR specificity for the chemokine XCL1 and its receptor XCR1.

Authors:  Jamie C Fox; Monica A Thomas; Acacia F Dishman; Olav Larsen; Takashi Nakayama; Osamu Yoshie; Mette Marie Rosenkilde; Brian F Volkman
Journal:  Sci Signal       Date:  2019-09-03       Impact factor: 8.192

5.  The expression of FLNA and CLU in PBMCs as a novel screening marker for hepatocellular carcinoma.

Authors:  Rathasapa Patarat; Shoji Riku; Pattapon Kunadirek; Natthaya Chuaypen; Pisit Tangkijvanich; Apiwat Mutirangura; Charoenchai Puttipanyalears
Journal:  Sci Rep       Date:  2021-07-21       Impact factor: 4.379

6.  Immunogenic necroptosis in the anti-tumor photodynamic action of BAM-SiPc, a silicon(IV) phthalocyanine-based photosensitizer.

Authors:  Ying Zhang; Ying-Kit Cheung; Dennis K P Ng; Wing-Ping Fong
Journal:  Cancer Immunol Immunother       Date:  2020-08-24       Impact factor: 6.968

7.  Ovarian cancer chemokines may not be a significant barrier during whole tumor antigen dendritic-cell vaccine and adoptive T-cell immunotherapy.

Authors:  Emese Zsiros; Denarda Dangaj; Carl H June; Lana E Kandalaft; George Coukos
Journal:  Oncoimmunology       Date:  2015-10-19       Impact factor: 8.110

8.  Chemoattractant Receptors BLT1 and CXCR3 Regulate Antitumor Immunity by Facilitating CD8+ T Cell Migration into Tumors.

Authors:  Zinal S Chheda; Rajesh K Sharma; Venkatakrishna R Jala; Andrew D Luster; Bodduluri Haribabu
Journal:  J Immunol       Date:  2016-07-27       Impact factor: 5.422

Review 9.  NF-κB, inflammation, immunity and cancer: coming of age.

Authors:  Koji Taniguchi; Michael Karin
Journal:  Nat Rev Immunol       Date:  2018-01-22       Impact factor: 53.106

Review 10.  Common gamma chain cytokines in combinatorial immune strategies against cancer.

Authors:  Stephanie R Pulliam; Roman V Uzhachenko; Samuel E Adunyah; Anil Shanker
Journal:  Immunol Lett       Date:  2015-11-17       Impact factor: 3.685

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.